Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other

Tags
Quarterly results

SOPHIRIS BIO INC. (SPHS) Create: Alert

All | News | Filings
Date FiledTypeDescription
09/01/2022 SEC STAFF ACTION Form SEC STAFF ACTION - SEC Staff Action: ORDER
04/29/2020 25-NSE Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities:
04/03/2020 8-K Other Events
03/31/2020 8-K Quarterly results
03/11/2020 8-K Quarterly results
02/14/2020 SC 13G/A ARMISTICE CAPITAL, LLC reports a 5% stake in Sophiris Bio Inc.
12/23/2019 4 Form 4 - Statement of changes in beneficial ownership of securities:
12/23/2019 4 Form 4 - Statement of changes in beneficial ownership of securities:
12/23/2019 4 HULME ALLISON (COO) has filed a Form 4 on SOPHIRIS BIO INC.
Txns: Granted 123,000 options to buy @ $0.36, valued at $44.3k
12/23/2019 8-K Quarterly results
12/13/2019 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
12/13/2019 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
12/09/2019 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
11/12/2019 S-1 Form S-1 - General form for registration of securities under the Securities Act of 1933:
11/08/2019 10-Q Quarterly Report for the period ended September 30, 2019
11/07/2019 8-K Quarterly results
Docs: "Sophiris Bio Inc."
10/22/2019 8-K Quarterly results
10/08/2019 8-K/A Quarterly results
09/12/2019 8-K Quarterly results
09/06/2019 SC 13G ARMISTICE CAPITAL, LLC reports a 7.6% stake in Sophiris Bio Inc.
09/06/2019 D Form D - Notice of Exempt Offering of Securities:
08/27/2019 8-K Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits
Docs: "Form of Pre-Funded Common Share Purchase Warrant",
"Form of Series A Common Share Purchase Warrant",
"Opinion of Fasken Martineau DuMoulin LLP",
"Opinion of Cooley LLP",
"Form of Securities Purchase Agreement, by and between the Company and the Purchaser",
"Press Release"
08/27/2019 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
08/09/2019 10-Q Quarterly Report for the period ended June 30, 2019
08/09/2019 8-K Quarterly results
Docs: "Sophiris Bio Reports Second Quarter 2019 Financial Results and Recent Corporate Highlights SAN DIEGO and VANCOUVER, British Columbia, August 9, 2019 – Sophiris Bio Inc. , a biopharmaceutical company studying topsalysin , a first-in-class, pore-forming protein, in late-stage clinical trials for the treatment of patients with urological diseases, today reported financial results for the second quarter 2019 and recent corporate highlights. “During the second quarter of 2019, we received positive feedback from the EMA regarding the design of our Phase 3 clinical trial for localized prostate cancer which was a significant step forward in our development of topsalysin,” said Randall E. Woods, president and CEO of Sophiris. “We are now focused on our plan to fund this study and the Company going ..."
06/28/2019 4 Form 4 - Statement of changes in beneficial ownership of securities:
06/28/2019 4 HEPPELL JAMES L (Director) has filed a Form 4 on SOPHIRIS BIO INC.
Txns: Granted 20,000 options to buy @ $0.7782, valued at $15.6k
06/28/2019 4 Form 4 - Statement of changes in beneficial ownership of securities:
06/28/2019 4 Form 4 - Statement of changes in beneficial ownership of securities:
06/28/2019 8-K Quarterly results
06/07/2019 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
05/09/2019 10-Q Quarterly Report for the period ended March 31, 2019
05/09/2019 8-K Quarterly results
Docs: "Sophiris Bio Reports First Quarter 2019 Financial Results SAN DIEGO and VANCOUVER, British Columbia, May 9, 2019 – Sophiris Bio Inc. , a biopharmaceutical company developing topsalysin , a first-in-class, pore-forming protein, in late-stage clinical trials for the treatment of patients with urological diseases, today reported financial results for the first quarter of 2019. “We continue to have dialog with the European Medicines Agency regarding the design for a potential Phase 3 clinical trial, which we developed with input from our scientific advisory board for the treatment of localized prostate cancer,” said Randall E. Woods, president and CEO of Sophiris. “We anticipate obtaining formal scientific advice from the EMA before the end of the second quarter and look forward to taking the ..."
04/30/2019 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy